Home » Stocks » EXAS

Exact Sciences Corporation (EXAS)

Stock Price: $121.89 USD -0.02 (-0.02%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
After-hours: $121.95 +0.06 (0.05%) Jun 11, 7:49 PM
Market Cap 20.91B
Revenue (ttm) 1.55B
Net Income (ttm) -774.00M
Shares Out 169.43M
EPS (ttm) -4.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $121.89
Previous Close $121.91
Change ($) -0.02
Change (%) -0.02%
Day's Open 122.00
Day's Range 119.88 - 124.49
Day's Volume 1,598,788
52-Week Range 70.75 - 159.54

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?

1 week ago - Zacks Investment Research

Investors are optimistic about Exact Sciences (EXAS) on solid first-quarter performance and strategic partnerships.

2 weeks ago - Zacks Investment Research

Modeling data exhibits efficacy of Exact Sciences' (EXAS) Cologuard compared to FIT and other colorectal cancer diagnostic options.

2 weeks ago - Zacks Investment Research

They're well below peak levels set earlier this year. But they could be huge winners over the long run.

Other stocks mentioned: CRSP, TDOC, TWST
2 weeks ago - The Motley Fool

With the trading day more than halfway over, the markets had dipped after a relatively strong start to the day.

Other stocks mentioned: BSX, TAP, TAP.A, ADSK, AESE, GPS, STZ ...
2 weeks ago - 24/7 Wall Street

MADISON, Wis., May 24, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following virtual conferences and invited investors to par...

2 weeks ago - PRNewsWire

MADISON, Wis., May 21, 2021 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today highlights data from one oral and one poster presentation being featured at the 2021 Digestive Disease Week® (DDW®) ...

3 weeks ago - PRNewsWire

Exact Sciences (EXAS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more streng...

3 weeks ago - Zacks Investment Research

The company's Cologuard DNA test appears to be in good shape to maintain its market leadership.

3 weeks ago - The Motley Fool

MADISON, Wis., May 19, 2021 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced new data on its cancer tests and treatment guidance tools will be ...

3 weeks ago - PRNewsWire

Buying the stock market weakness? Or staying on the sidelines?

Other stocks mentioned: DKNG, PYPL, SHOP, TSLA
3 weeks ago - Zacks Investment Research

MADISON, Wis., May 18, 2021 /PRNewswire/ -- The United States Preventive Services Task Force (USPSTF) today released its final colorectal cancer screening recommendation that screening begin at age 45.

3 weeks ago - PRNewsWire

Despite ongoing pandemic-related headwinds, the medical diagnostic test maker's revenue grew. So how will it perform as those headwinds dissipate?

4 weeks ago - The Motley Fool

The company has other more significant growth drivers.

4 weeks ago - The Motley Fool

Falling costs are ushering in a new era of screening for a dreaded disease.

Other stocks mentioned: GH, PACB
4 weeks ago - The Motley Fool

CareDx just posted 76% year-over-year revenue growth for the first quarter and raised its 2021 guidance.

Other stocks mentioned: CDNA, GH
1 month ago - The Motley Fool

It definitely made investors a lot of money over the last decade. And its future could be brighter than the past.

Other stocks mentioned: BEAM, MRNA, NTLA, REGN, XBI
1 month ago - The Motley Fool

Exact Sciences' (EXAS) first-quarter 2021 revenues improved year over year led by growth in Precision Oncology, COVID-19 testing and Screening revenues.

1 month ago - Zacks Investment Research

There was a big asterisk with the company's improved bottom line.

1 month ago - The Motley Fool

Exact Sciences (EXAS) delivered earnings and revenue surprises of 82.69% and 4.50%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

MADISON, Wis., May 4, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $402.1 million for the first quarter ended March 31, 2021, compared t...

1 month ago - PRNewsWire

ARK Invest has been one of the most popular themes of late in the markets, outperforming many other funds and solidifying its place among the big players in the investments world.

Other stocks mentioned: BIDU, ROKU, SHOP, SPOT, SQ, TDOC, TSLA ...
1 month ago - 24/7 Wall Street

MADISON, Wis., May 3, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conferences and invited investors to participate ...

1 month ago - PRNewsWire

MADISON, Wis., April 28, 2021 /PRNewswire/ -- Exact Sciences (NASDAQ: EXAS) today announces study results published in Mayo Clinic Proceedings showing that Cologuard (mt-sDNA) is the most cost-effective...

1 month ago - PRNewsWire

These three stocks have just one thing in common: The potential for explosive growth.

Other stocks mentioned: JD, U
1 month ago - The Motley Fool

Digital wallets and genomics will transform the world in coming years.

Other stocks mentioned: PYPL
1 month ago - The Motley Fool

ARK Invest has been one of the most popular themes of late in the markets, outperforming many other funds and solidifying its place among the big players in the investments world.

Other stocks mentioned: BIDU, ROKU, SHOP, SPOT, SQ, TDOC, TSLA ...
1 month ago - 24/7 Wall Street

MADISON, Wis., April 14, 2021 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that it has completed its previously announced acquisition of Ashion Analytics, LLC.

1 month ago - PRNewsWire

MADISON, Wis., April 8, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its first quarter 2021 financial results after the close of the U.S. fi...

2 months ago - PRNewsWire

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?

2 months ago - Zacks Investment Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Other stocks mentioned: ANSS, BFAM, DSKE, GFI
2 months ago - Zacks Investment Research

Ark Funds hosted an investor webinar Tuesday, sharing ideas on several industries and portfolio components, including a discussion on some names in the genomics space. Ark Funds On Genomics: Ark Funds i...

Other stocks mentioned: CAPA
3 months ago - Benzinga

MADISON, Wis., Feb. 22, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following virtual conferences and invited investors to pa...

3 months ago - PRNewsWire

These two companies have exciting long-term prospects.

Other stocks mentioned: GH
3 months ago - The Motley Fool

The company reported disappointing Q4 results.

3 months ago - The Motley Fool

Exact Sciences' (EXAS) legacy Screening business sees an uptick in revenues in Q4 earnings.

3 months ago - Zacks Investment Research

Due to an accounting charge taken because of an acquisition, the company was deep in the red on the bottom line.

3 months ago - The Motley Fool

Shares of Exact Sciences (NASDAQ:EXAS) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 59.46% over the past year to ($0.15), which beat the ...

3 months ago - Benzinga

MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $466.3 million for the fourth quarter ended Dec. 31, 2020 and $1,49...

3 months ago - PRNewsWire

MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has entered into an agreement to acquire Ashion Analytics, LLC (Ashion) from The Translational Ge...

3 months ago - PRNewsWire

Exact Sciences (NASDAQ:EXAS) announces its next round of earnings this Tuesday, February 16. Here is Benzinga's look at Exact Sciences's Q4 earnings report.

3 months ago - Benzinga

Exact Sciences (EXAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

4 months ago - Zacks Investment Research

Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Strength in Precision Oncology business is likely to have continued to aid Exact Sciences' (EXAS) performance in the fourth quarter of 2020 amid the coronavirus-led economic doldrums.

4 months ago - Zacks Investment Research

MADISON, Wis., Feb. 1, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conferences and invited investors to participate...

4 months ago - PRNewsWire

MADISON, Wis., Feb. 1, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its fourth quarter 2020 financial results after the close of the U.S. fi...

4 months ago - PRNewsWire

Stock Indexes Hold Tough, But Leaders Struggle: Datadog, Exact Sciences, Freeport McMoRan In Focus

YouTube video

Stock indexes hold tough, but leaders struggle: Datadog, Exact Sciences, Freeport McMoRan in focus. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock ...

Other stocks mentioned: DDOG, FCX
4 months ago - Investors Business Daily

Multi-cancer screening is the holy grail for the test industry. Exact Sciences is pursuing it by acquiring complementary companies.

4 months ago - Seeking Alpha

Exact Sciences' (EXAS) strength in Screening revenue along with a robust COVID-19 testing arm are likely to have boosted the top line significantly.

4 months ago - Zacks Investment Research

MADISON, Wis., Jan. 12, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) announced data published today in Cancer Prevention Research, a Journal of the American Association for Cancer Research, ...

5 months ago - PRNewsWire

About EXAS

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX ... [Read more...]

Industry
Diagnostics & Research
Founded
1995
CEO
Kevin Conroy
Employees
4,800
Stock Exchange
NASDAQ
Ticker Symbol
EXAS
Full Company Profile

Financial Performance

In 2020, Exact Sciences's revenue was $1.49 billion, an increase of 70.19% compared to the previous year's $876.29 million. Losses were -$848.53 million, 910.2% more than in 2019.

Financial Statements

Analyst Forecasts

According to 16 analysts, the average rating for Exact Sciences stock is "Strong Buy." The 12-month stock price forecast is 156.89, which is an increase of 28.71% from the latest price.

Price Target
$156.89
(28.71% upside)
Analyst Consensus: Strong Buy